Showing 3321-3330 of 5646 results for "".
- Envision Announces Dates, Calls for Submissions for 2020 Conferenceshttps://modernod.com/news/envision-announces-dates-calls-for-submissions-for-2020-conferences/2477082/Envision announced that it is now accepting submissions for clinical education and research presentations for its two annual conferences in 2020: Envision Conference West, April 3-4, UT Health San Antonio Department of Occupational Therapy in San Antonio, Texas; and Envision Conference East, Augu
- Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Diseasehttps://modernod.com/news/integrated-clinical-trial-analyses-further-substantiate-that-teprotumumab-significantly-improves-debilitating-effects-of-thyroid-eye-disease/2477063/Horizon Therapeutics announced integrated, pooled efficacy data from the phase 2 and phase 3 clinical trials of teprotumumab for the treatment of active thyroid eye disease (TED) compared to placebo. The results support prior analyses of significant reductions in inflammation, proptosis (eye bulg
- Eyenovia Advances MicroLine for the Treatment of Presbyopia; Reprioritizes Late-Stage Ophthalmology Pipelinehttps://modernod.com/news/eyenovia-advances-microline-for-the-treatment-of-presbyopia-reprioritizes-late-stage-ophthalmology-pipeline/2477052/Eyenovia announced that the company is advancing the development of its MicroLine program for the improvement in near vision in patients with presbyopia toward phase 3 development. As a result of prioritizing MicroLine in tandem with its MicroPine (progressive myopia) and MicroSta
- Sight Sciences: International MIGS Study Confirms Long-Term Safety and Efficacy of the OMNI Surgical System Predicate Device (VISCO360)https://modernod.com/news/sight-sciences-international-migs-study-confirms-long-term-safety-and-efficacy-of-the-omni-surgical-system-predicate-device-visco360/2477032/Sight Sciences announced a new, single center study of glaucoma surgery patients published in the July 2019 issue of Clinical Ophthalmology, which shows that ab-interno microcatheterization and 360˚ viscodilation of Schlemm’s Canal using one of the OMNI
- ObjectiveEd Joins Microsoft’s AI for Accessibility Program to Develop Braille AI Tutor Platformhttps://modernod.com/news/objectiveed-joins-microsofts-ai-for-accessibility-program-to-develop-braille-ai-tutor-platform/2477020/ObjectiveEd has joined Microsoft Corp.’s AI for Accessibility program to help further its efforts in maximizing educational outcomes for children with disabilities. As a component of ObjectiveEd’s inclusion in the program, Microsoft has awarded ObjectiveEd a grant that will provide ObjectiveEd wi
- Eyevance Pharmaceuticals Acquires Tobradex ST and Natacynhttps://modernod.com/news/eyevance-pharmaceuticals-acquires-tobradex-st-and-natacyn/2477011/Eyevance Pharmaceuticals has announced the acquisition of Tobradex ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% and Natacyn (natamycin ophthalmic suspension) 5% from Novartis. Terms of the deal were not disclosed. “The acquisition of Tobradex ST and Natacyn further
- Optos Unveils Silverstone Combined Ultra-Widefield Retinal Imaging Device and UWF-Guided Swept Source OCThttps://modernod.com/news/optos-unveils-silverstone-combined-ultra-widefield-retinal-imaging-device-and-uwf-guided-swept-source-oct/2476998/Optos has announced the launch of Silverstone at the American Academy of Ophthalmology in San Francisco. Silverstone is the first-of-its-kind, combining world-leading ultra-widefield retinal imaging with integrated, image-guided, swept source OCT. Silverstone produces a 200° single capture
- Harbour BioMed Announces Completion of Phase 2 Study in China of HBM9036 In Patients With Moderate-to-Severe Dry Eye Diseasehttps://modernod.com/news/harbour-biomed-announces-completion-of-phase-2-study-in-china-of-hbm9036-in-patients-with-moderate-to-severe-dry-eye-disease/2476993/Harbour BioMed (HBM) announced completion of a phase 2 study in China of HBM9036 (tanfanercept), a new, investigational TNF receptor-1 fragment, in adult patients with moderate-to-severe dry eye disease (DED). The study results, combined with previous results from HBM’s partner HanAll’s clinical
- Neurolign Acquires of Eye Diagnostic Technology Company Neuro Kineticshttps://modernod.com/news/neurolign-acquires-of-eye-diagnostic-technology-company-neuro-kinetics/2476981/Neurolign Technologies announced the acquisition of Neuro Kinetics of Pittsburgh, Pennsylvania, a provider of clinical eye-tracking and noninvasive neurofunctional diagnostic testing, delivering neurofunctional assessments. Terms of the deal were not disc
- LLamasoft Partners with Global Eye Bank, Eversighthttps://modernod.com/news/llamasoft-partners-with-global-eye-bank-eversight/2476974/LLamasoft has announced its partnership with Eversight, a nonprofit organization dedicated to restoring sight and preventing blindness through eye donation, corneal transplantation, and vision research. Eversight will utilize LLamasoft’s solutions to make data-driven decisions that more accuratel